These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1685924)

  • 21. Enterotachogram analysis to distinguish irritable bowel syndrome from Crohn's disease.
    Craine BL; Silpa ML; O'Toole CJ
    Dig Dis Sci; 2001 Sep; 46(9):1974-9. PubMed ID: 11575452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.
    Palsson OS; Morteau O; Bozymski EM; Woosley JT; Sartor RB; Davies MJ; Johnson DA; Turner MJ; Whitehead WE
    Dig Dis Sci; 2004 Aug; 49(7-8):1236-43. PubMed ID: 15387352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computerized auscultation applied to irritable bowel syndrome.
    Craine BL; Silpa M; O'Toole CJ
    Dig Dis Sci; 1999 Sep; 44(9):1887-92. PubMed ID: 10505730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for the hormonal status of somatostatin in man.
    Zyznar ES; Pietri AO; Harris V; Unger RH
    Diabetes; 1981 Oct; 30(10):883-6. PubMed ID: 6115787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
    Shekhar C; Monaghan PJ; Morris J; Issa B; Whorwell PJ; Keevil B; Houghton LA
    Gastroenterology; 2013 Oct; 145(4):749-57; quiz e13-4. PubMed ID: 23872499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma somatostatin in normal subjects and in various diseases: increased levels in somatostatin-producing tumors.
    Saito H; Saito S
    Horm Metab Res; 1982 Feb; 14(2):71-6. PubMed ID: 6121747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome.
    Gorard DA; Libby GW; Farthing MJ
    Gut; 1994 Feb; 35(2):203-10. PubMed ID: 8307470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status.
    Houghton LA; Brown H; Atkinson W; Morris J; Fell C; Whorwell PJ; Lockhart S; Keevil B
    Aliment Pharmacol Ther; 2009 Nov; 30(9):919-29. PubMed ID: 19691669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome.
    El-Salhy M; Hatlebakk JG; Gilja OH; Hausken T
    Peptides; 2015 May; 67():12-9. PubMed ID: 25765365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome.
    Awad RA; Llorens F; Camelo AL; Sánchez M
    Acta Gastroenterol Latinoam; 2000; 30(3):169-75. PubMed ID: 10975022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there an irritable bladder in the irritable bowel syndrome?
    Monga AK; Marrero JM; Stanton SL; Lemieux MC; Maxwell JD
    Br J Obstet Gynaecol; 1997 Dec; 104(12):1409-12. PubMed ID: 9422022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care.
    Sanders DS; Carter MJ; Hurlstone DP; Pearce A; Ward AM; McAlindon ME; Lobo AJ
    Lancet; 2001 Nov; 358(9292):1504-8. PubMed ID: 11705563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin and symptomatic relief of irritable bowel syndrome.
    Talley NJ; Turner I; Middleton WR
    Lancet; 1987 Nov; 2(8568):1144. PubMed ID: 2890035
    [No Abstract]   [Full Text] [Related]  

  • 34. Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome?
    Lustyk MK; Jarrett ME; Bennett JC; Heitkemper MM
    Gastroenterol Nurs; 2001; 24(3):129-37. PubMed ID: 11847862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiological correlates of colonic motility in patients with irritable bowel syndrome.
    Bassotti G; Crowell MD; Cheskin LJ; Chami TN; Schuster MM; Whitehead WE
    Z Gastroenterol; 1998 Sep; 36(9):811-7. PubMed ID: 9795410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients.
    Bouchoucha M; Faye A; Devroede G; Arsac M
    Biomed Pharmacother; 2000 Aug; 54(7):381-7. PubMed ID: 10989977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics.
    Sullivan MA; Cohen S; Snape WJ
    N Engl J Med; 1978 Apr; 298(16):878-83. PubMed ID: 345122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
    Awad RA; Cordova VH; Dibildox M; Santiago R; Camacho S
    Acta Gastroenterol Latinoam; 1997; 27(4):247-51. PubMed ID: 9401097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating somatostatin concentrations in healthy and cirrhotic subjects.
    Verrillo A; de Teresa A; Martino C; Pinto M; Golia R
    Metabolism; 1986 Feb; 35(2):130-5. PubMed ID: 2868381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irritable bowel syndrome in office-based practice in the United States.
    Everhart JE; Renault PF
    Gastroenterology; 1991 Apr; 100(4):998-1005. PubMed ID: 2001837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.